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Abstract
Amyotrophic lateral sclerosis (ALS) is a relentlessly progressive neurodegenerative
condition that is invariably fatal, usually within 3 to 5 years of diagnosis. The etiol-
ogy of ALS remains unresolved and no effective treatments exist. There is therefore
a desperate and unmet need for discovery of disease mechanisms to guide novel
therapeutic strategies. The single major risk factor for ALS is aging, yet the molecu-
lar consequences of cell type‐specific aging remain understudied in this context.
Induced pluripotent stem cells (iPSCs) have transformed the standard approach of
examining human disease, generating unlimited numbers of disease‐relevant cells
from patients, enabling analysis of disease mechanisms and drug screening. How-
ever, reprogramming patient cells to iPSCs reverses key hallmarks of cellular age.
Therefore, although iPSC models recapitulate some disease hallmarks, a crucial chal-
lenge is to address the disparity between the advanced age of onset of neurodegen-
erative diseases and the fetal‐equivalent maturational state of iPSC‐derivatives.
Increasing recognition of cell type‐specific aging paradigms underscores the impor-
tance of heterogeneity in ultimately tipping the balance from a state of compen-
sated dysfunction (clinically pre‐symptomatic) to decompensation and progression
(irreversible loss of neurological functions). In order to realize the true promise of
iPSC technology in ALS, efforts need to prioritize faithfully recapitulating the clinical
pathophysiological state, with proportionate emphasis on capturing the molecular
sequelae of both cellular age and non‐cell‐autonomous disease mechanisms within
this context.
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1 | INTRODUCTION
As life expectancy of the population increases, the prevalence of
aging‐associated disorders, such as amyotrophic lateral sclerosis
(ALS) and other forms of neurodegeneration, is also increasing (Lutz,
Sanderson, & Scherbov, 2008). Regrettably, in contrast to the
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CNS, central nervous system; dMMP, matrix metalloproteinase 1; ESC, embryonic stem
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escalating affliction that these neurological disorders have on soci-
ety, effective therapeutics are far from realization. Overall, animal
models have provided crucial insight across the range of basic and
applied neuroscience. However, despite hundreds of clinical trials
based on pre‐clinical studies using animal models, not one has
yielded a significant therapy that is of real clinical impact for ALS.
This may reflect crucial interspecies differences, which are increas-
ingly documented across molecular, cellular, circuit‐level, functional,
and anatomical domains. Human postmortem tissue overcomes this
problem to some degree, but it also represents an advanced stage of
the disease process, making it impossible to capture initiating molec-
ular pathogenic events.
Importantly, these limitations can now be overcome, at least in
part, by using induced pluripotent stem cells (iPSCs). Differentiating
pluripotent stem cells into enriched cell type‐specific populations
presents an exciting opportunity to attain large numbers of patient‐
specific cells in vitro, to model disease, and test drug candidates.
The field has seen a rapid advancement in the establishment of iPSC
technology with key molecular pathogenic signatures detected
across a wide spectrum of disease models (Dimos et al., 2008; Hall
et al., 2017; Park et al., 2008). Despite this progress, current differ-
entiation protocols produce cells that possess fetal‐equivalent matu-
ration, which contrasts greatly with age‐related pathologies like late‐
onset neurodegenerative diseases (Arbab, Baars, & Geijsen, 2014;
Liu, Ding, & Izpisua Belmonte, 2012; Luisier et al., 2018; Mertens
et al., 2015; Miller et al., 2013; Patani et al., 2012; Vera, Bosco, &
Studer, 2016). Whilst relevant phenotypes have successfully been
reported in iPSC models, they resemble early stage pathogenic
events, rather than age‐related degenerative features of the condi-
tion. Consequently, to accurately elucidate age‐related phenotypes,
the erasure of the hallmarks of biological age caused by reprogram-
ming should arguably be reinstated. Strategies to circumvent this
hurdle involve inducing cellular age using a variety of approaches
discussed herein. Indeed proof of principle studies have shown that
this approach enables iPSC models to capture some authentic aging‐
related phenotypes (Mertens et al., 2015; Miller et al., 2013; Paavi-
lainen et al., 2018; Vera et al., 2016). We review strategies that have
been developed to induce cellular age in order to overcome the reju-
venating effect of reprogramming. These approaches should further
advance the molecular, cellular, and functional production of patient‐
derived iPSC platforms to investigate ALS with fidelity and precision.
2 | INDUCING PLURIPOTENCY REVERSES
KEY HALLMARKS OF CELLULAR AGE
Aging is a highly pleiotropic process making it difficult to discern
between the accumulation of damage throughout life or conversely
an active program. Cumulatively, aging precipitates alterations that
damage both structural and functional aspects of cellular physiology,
which are summarized in Figure 1 and have been extensively
reviewed elsewhere (Lopez‐Otin, Blasco, Partridge, Serrano, & Kroe-
mer, 2013). Reprogramming of somatic cells back to the pluripotent
state effectively deletes molecular traces of aging and maturation
that were acquired during the life of the somatic cell, resetting the
biological clock so that adult cells become tantamount to embryonic
stem cells (ESCs) (Miller et al., 2013; Studer, Vera, & Cornacchia,
2015). Reprogramming also has the capability of reversing aging‐re-
lated epigenomic alterations, such as DNA methylation marks that
human tissues acquire over time. Indeed the restoration of DNA
methylation during in vitro differentiation can serve as a marker of
iPSC maturity (Horvath, 2013).
Induced pluripotent stem cells have been successfully differenti-
ated into myriad cell types relevant to ALS (reviewed in Patani,
2016; Tyzack, Lakatos, & Patani, 2016). These directed differentia-
tion protocols generate cell types that represent fetal, rather than
adult, maturity. We and others assessed this issue by comparing gen-
ome‐wide expression profiles of human pluripotent stem cells, multi-
potent neural precursor cells, and terminally differentiated neurons
with fetal and adult postmortem counterparts (Mertens et al., 2015;
Miller et al., 2013; Patani et al., 2012). This was supported by a
more recent global gene expression and network analysis, investigat-
ing iPSC‐derived motor neurons, which confirmed that these were
fetal in maturational state based on their transcriptomic profiles (Ho
et al., 2016; Luisier et al., 2018) (Figure 2).
3 | DIRECTED DIFFERENTIATION OF IPSCS
PERMITS CAPTURE OF EARLY DISEASE
PHENOTYPES
The first iPSC model of human neurological disease studied spinal
muscular atrophy (SMA) type 1, which selectively affects lower motor
neurons and presents early in the postnatal period. This study success-
fully recapitulated motor neuron degeneration and death. However,
even in this early‐onset disease there are key postnatal motor neuron
defects that appear in the absence of functioning SMN (survival motor
neuron) protein, such as axon truncation, loss of NMJs, and reduction
in branching and outgrowth (Ebert et al., 2009). Accordingly, iPSC‐
derived motor neurons from SMA type I patients developed more
widespread disease hallmarks only after extended in vitro culture for
several months (Corti et al., 2012; Ebert et al., 2009).
Conventional (“fetal‐like”) iPSC‐derived motor neurons and astro-
cytes have also demonstrated clear value in capturing early biochem-
ical phenotypes of ALS in a cell type‐specific fashion (Hall et al.,
2017; Luisier et al., 2018; Simone et al., 2018; Tyzack et al., 2017).
Although the iPSC technology allows capture of the earliest molecu-
lar pathogenic events, elucidating the contribution of cell type‐speci-
fic aging programs is a key consideration for future disease
modeling. Therefore, despite considerable progress, cellular rejuvena-
tion resulting from reprogramming to the pluripotent state raises
concern over missing salient age‐related cellular phenotypes (Hu
et al., 2010; Patterson et al., 2012). To model ALS with fidelity,
inducing a cellular age that resembles late adulthood is desirable in
order to discriminate age‐related cellular phenotypes (Figure 2).
Despite challenges in inducing cellular age of iPSC‐derivatives, vari-
ous approaches have been proposed for manipulating the aging pro-
cess, largely inspired by important work in animal models.
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3.1 | Inducing cellular aging—lessons from in vivo
studies
Experimental models, including heterochronic (differentially aged)
parabiosis, where the circulatory systems of young and old mice are
surgically connected, have identified systemic factors that influence
aging (Conboy, Conboy, & Rando, 2013). These experiments demon-
strated that not only does blood from young mice rejuvenate older
mice, but young mice undergo accelerated aging when subjected to
blood from older mice (Villeda et al., 2014). Although the identity of
all specific aging factors in human plasma remains incomplete, signifi-
cant insights into the molecular underpinnings of this process have
recently been achieved. Human umbilical cord plasma was shown to
revitalize the hippocampus, and tissue inhibitor of metalloproteinases
2 (TIMP2) was identified as a plasma protein that increases synaptic
plasticity and cognitive function in aged mice (Castellano et al.,
2017). In vivo studies, using both systemic administration and inhibi-
tion of plasma candidates found in young blood, have revealed other
factors that slow age‐dependent neural deterioration and induce
reversing of aging, including (a) growth differentiation factor 11 (Kat-
simpardi et al., 2014); (b) oxytocin (Elabd et al., 2014); and (c) Delta–
Notch signaling (Honoki, 2017). Conversely, using a mouse model to
study muscle stem cells, activation of the canonical Wnt signaling
pathway promoted conversion from a myogenic to an aging‐associ-
ated fibrogenic lineage, thereby implicating a possible bidirectional
instructive regulation (Brack et al., 2007).
Key drivers of these aforementioned regulators of aging have
also been studied. Recognition that mouse aging involves the loss of
hypothalamic stem cells inspired ablation studies which consistently
led to accelerated aging and lifespan shortening (Zhang et al., 2013,
2017). Conversely, aging delay and lifespan extension were attained
in middle‐aged mice when implanted with healthy hypothalamic stem
cells. This recovery of physiological processes was shown to be
mediated, at least in part, through release of exosomal miRNAs into
the cerebrospinal fluid (Zhang et al., 2017). Whether this in turn
leads to a series of downstream signaling events in a theoretical
aging‐cascade remains to be studied. Given the myriad of aging regu-
lators that have been discovered, it is likely that there are multiple
sequential steps, with various molecular sub‐regulators at different
end‐organ sites that ultimately influence the overall net rate of aging
in a given tissue.
4 | INDUCING CELLULAR AGING IN IPSC ‐
DERIVATIVES
An important challenge in the iPSC field is to specifically modulate
the biological age of cultures independently of their chronological
age. As the sequence of iPSC differentiation in vitro reflects lineage
determination during embryogenesis, the reason a prolonged culture
enables maturation is likely due to the presence of a built‐in clock
that guides the tempo and direction of cell fate. This cell‐au-
tonomous “pacemaker” phenomenon is supported by the finding that
in vitro neurogenesis is temporally cataloged into distinct phases,
and mirrors in vivo neural development (Hu et al., 2010). These find-
ings, which are species‐specific, suggest that an internal timer regu-
lates cellular maturation and aging. This raises the prospect of
predictably manipulating master regulators of this mechanism experi-
mentally, which may in turn permit the accurate delineation of age‐
related phenotypes (Shi, Kirwan, Smith, Robinson, & Livesey, 2012).
Here, we discuss the approaches that have been attempted to
induce cellular aging of iPSC‐derived neurons. Importantly, we distin-
guish the approaches that truly attempt to model cellular aging (dis-
cussed below; see Table 1), from those that merely expedite routes
of generating fetal‐equivalent neurons (Figure 3; and Supporting
Information Box S1).
4.1 | Progerin expression
Although the systemic factors that induce aging are still mostly
unidentified, some genetic mutations have been found that acceler-
ate aging. Hutchinson–Gilford progeria syndrome (HGPS), caused by
a point mutation in the lamin A (LMNA) gene, is one such example
of a disease characterized by accelerated aging (Scaffidi & Misteli,
2008). Alternative post‐transcriptional modification of the LMNA
mRNA transcript results in translation into a truncated farnesylated
form of lamin A protein, termed progerin. Lamins are vital con-
stituents of the nuclear envelope and are integral to most aspects of
nuclear metabolism. Progerin itself acts to damage and shorten
telomeres, and activates DNA damage checkpoints, inhibiting cell
proliferation and encouraging senescence. Modeling HGPS in iPSC‐
derived neurons revealed cell type‐specific protection from the aging
effects of progerin as neurons are deficient in lamin A protein (Liu
et al., 2011), as a result of expression of microRNA 9 (Nissan et al.,
2012).
Although progerin overexpression has not yet been utilized in an
iPSC model of ALS, it has been applied to iPSC‐derived midbrain
dopaminergic neurons in a Parkinson's disease (PD) model (Miller
et al., 2013). This approach successfully generated an aged pheno-
type, as demonstrated by neuromelanin accumulation, marked den-
drite degeneration, loss of tyrosine hydroxylase expression, and
enlarged mitochondria or Lewy body‐precursor inclusions, producing
a more representative PD model. Although this indicates that pro-
gerin exposure is sufficient to induce some aging‐associated markers,
questions remain as to whether this approach faithfully captures key
aspects of authentic neuronal aging.
4.2 | Telomerase inhibition
Another approach to induce aging involves altering one of the classic
hallmarks of aging, telomere shortening. With age, the telomere pre-
serving enzyme, telomerase is down regulated and telomeres get
successively shorter with each cell cycle. Vera and coworkers utilized
a pharmacological approach to reduce telomerase activity with a
small molecule inhibitor, thereby shortening telomeres of iPSC‐
derivatives. The iPSC‐derived neurons with shorter telomeres exhib-
ited aging‐related features, including DNA damage, mitochondrial
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ROS generation, and dendritic atrophy (Vera et al., 2016). Although
this approach successfully produced some disease‐related features,
in a model of PD telomere length remained variable and the full
impact of telomere shortening on post mitotic cells has yet to be
systematically resolved.
4.3 | Transdifferentiation
An alternative approach to bypass the issue of the embryonic nature
of iPSCs is direct conversion of patient‐derived somatic cells into the
mature‐specific cell type of interest. In this way, reprogramming to
TABLE 1 Strategies to induce cellular aging
Method Detail Strengths Limitations References
Progerin overexpression Progerin overexpression to
induce aging in an induced
pluripotent stem cell (iPSC)
model of
neurodegeneration
Marked dendrite
degeneration, loss of
neuronal subtype‐specific
expression, enlarged
mitochondria, disease‐
specific inclusions
Does not capture all aspects
of aging
Miller et al. (2013)
Zhang et al. (2017)
Liu et al. (2011)
Nissan et al. (2012)
Scaffidi and Misteli (2008)
Telomere shortening Pharmacologically reduced
telomerase activity with a
small molecule inhibitor in
iPSC‐derived neurons
DNA damage, mitochondrial
ROS generation, and
dendrite degeneration
Telomere length remained
variable
Vera et al. (2016)
Harel et al. (2015)
Marion et al. (2009)
Transdifferentiation Direct conversion of patient‐
derived somatic cells into
mature‐specific cell type of
interest. Reprogramming is
circumvented, and cellular
age is preserved.
Retain age‐associated
transcription traits and
functional deficits of the
donor cell population.
Accumulation of mutant
protein aggregates, DNA
damage, heterochromatic
loss, cellular senescence,
and mitochondrial
dysfunction
Limited cellular supply
Reliant on knowing which
factors to express
Mertens et al. (2015)
Victor et al. (2018)
Son et al. (2011)
Park et al. (2012)
Tang et al. (2017)
Vierbuchen et al. (2010)
Telomere shortening
Telomerase manipulation
Transdiﬀerentiation
Direct conversion to functional neurons
3D strategies:
Organoids, Microﬂuidics
Co-cultures with astroglia
Cell culture
modifications
Induced 
cellular aging
Bioengineered substrates
surface rigidity
extracellular matrix cocktail
ROS
ROS
ROS
Toxic stress:
ROS, arsenic, pesticides
20 week0 week 5 week 10 week
Long-term culture
Overexpress proteins:
Progerin, MMP 
Genomic manipulation
CRISPR/Cas9
Telomere attrition
Circulating factors
TIMP2, microRNAs
F IGURE 3 Strategies to model cellular aging. Throughout maturation and aging somatic cells undergo functional and gene expression
alterations, which are considered to be crucial in the onset of neurodegenerative conditions such as ALS. The iPSC field has previously been
constrained by retained fetal‐like phenotypes within cultured motor neurons. Using induced cellular aging strategies and cell culture
modification approaches to model aging has significantly improved these approaches
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the embryonic state is circumvented and cellular age is preserved.
Mertens and coworkers directly converted aged donor fibroblasts
into neurons by overexpressing the proneural genes Ascl1 and Ngn2
combined with a cocktail of small molecules to enhance direct con-
version efficiency. Using transcriptional profiling, they demonstrated
that these cells retained their age‐associated transcription traits and
functional deficits of the donor cell population (Mertens et al.,
2015). This study was recently independently confirmed by Victor
et al. (2018), who used microRNA‐based direct neuronal conversion
of patient fibroblasts into neurons. The preservation of donor cellular
age here allowed the identification of phenotypes that were not evi-
dent using the conventional iPSC‐based directed differentiation. This
underscores the value of retaining donor cellular age status when
modeling late‐onset neurological disorders, and by comparison to
their iPSC‐derived counterparts, it is possible to discriminate age‐re-
lated cell type‐specific phenotypes.
Such strategies are clearly applicable to iPSCs from ALS patients.
Indeed, overexpression of key transcription factors involved in motor
neuron development (Olig2, Hb9, Asc1, Lhx3) transforms somatic
cells directly into induced motor neurons (Park et al., 2012; Son
et al., 2011). By applying these transcription factors to both primary
fibroblasts and iPSC‐derived cells, key aging hallmarks (DNA damage,
heterochromatin loss, and increased cellular senescence) were only
preserved with direct conversion to motor neurons and not with
induced pluripotency. As might be predicted, the iPSC‐derived motor
neurons were rejuvenated and failed to retain the crucial aging hall-
marks from their donors (Tang, Liu, Zang, & Zhang, 2017). This com-
parative analysis of transdifferentiation vs. reprogramming
demonstrates that transdifferentiation holds significant value for
modeling age‐related aspects of ALS pathobiology (Table 2).
5 | DO THESE STRATEGIES CAPTURE
AUTHENTIC CELL TYPE ‐SPECIFIC
SIGNATURES OF AGING?
Although the aforementioned proof of concept studies recapitulate
key aspects of cellular aging, each approach has potential limitations.
Therefore, cross‐comparison between these orthogonal methods to
identify reproducible and key attributes of cellular aging is crucial.
Equally important is comparing these data in a different model (e.g.,
mouse models or human postmortem studies) to evaluate cellular
aging in tissue, which we discuss further in this section. Noting that
two of the fundamentally implicated cell types in ALS are motor neu-
rons and astrocytes (recently reviewed in Serio & Patani, 2018), we
specifically discuss benchmark studies of aging in these cell types.
6 | MOTOR NEURONS
Motor neuron function progressively deteriorates with advancing
age as the individual transitions from adulthood into old age. Aging
is associated with slowing of gait, impaired balance, and deficits in
fine motor skills, which cumulatively precipitate increased falls risk
and carer dependence (Sorond et al., 2015). Although it is well
established that with age, skeletal muscle, and neuromuscular junc-
tions (NMJ) degenerate, the effect of age on motor neurons has only
recently been elucidated from human postmortem tissue. Depletion
of both upper and lower motor neurons and subsequent denervation
of skeletal muscle contributes to sarcopenia and strength decline in
elderly individuals (Rygiel, Grady, & Turnbull, 2014; Soreq et al.,
2017). The reduction in motor neuron soma counts is followed by a
decline in axonal density, with around 5% of axons lost every
10 years between the second and 10th decade of life (Kawamura,
Okazaki, O'Brien, & Dych, 1977). By examining α motor neurons
between species across a physiological age range, preservation of
somal size was accompanied by the accumulation of lipofuscin
deposits (cellular waste). Surprisingly, motor neurons did not atrophy
with age; however, there was a significant reduction in cholinergic
and glutaminergic synaptic inputs that directly abut motor neurons
(Maxwell et al., 2018). Thus, it is the shedding of synaptic inputs,
rather than motor neuron morphological changes that likely con-
tribute to age‐related motor dysfunction.
One protein strongly implicated in motor neuron aging is the cal-
cium‐dependent zinc containing endopeptidase, matrix metallopro-
teinase 1 (dMMP1). Using transcriptional profiling of a Drosophilia
model, Azpura and coworkers not only reported that dMMP1 expres-
sion is age‐dependent, but that expression also correlates with a decline
in motor function. Furthermore, by interrogating motor neuron tran-
scriptomes across an age range, they found that overexpression of
dMMP1 in young motor neurons mimics the effect of age on the motor
system, with reduced NMJ neurotransmission and behavioral climbing
deficits. Although MMP genes are crucial in the development of the
nervous system, these findings indicate they elicit damaging conse-
quences in later life (Azpurua, Mahoney, & Eaton, 2018). This combina-
tion of benefit in youth, but at the expense of harm post‐reproductive
age, defines dMMP1 as an antagonistically pleiotropic gene.
Whether aging differentially affects subtypes of motor neurons is
of great interest. Spinal motor neurons constitute a highly diverse
population with various subclasses differing in gene expression and
neuron function (William, Tanabe, & Jessell, 2003). Within motor neu-
ron pools, there is a varied mix of slow‐twitch fatigue resistant, fast‐
twitch fatigue resistant, and fast‐twitch fatigable α motor neurons.
Interestingly, these subclasses display varying degrees of vulnerability
to aging and degeneration in ALS, with fast‐twitch fatigable being the
most vulnerable and slow‐twitch fatigue resistance being the most
resistant (Chakkalakal, Nishimune, Ruas, Spiegelman, & Sanes, 2010).
The mechanisms responsible for driving this differential susceptibility
to motor neuron loss are likely to be multifactorial, with involvement
of both intracellular influences (e.g., mitochondrial dysfunction, oxida-
tive stress, calcium dyshomeostasis, and the accumulation of protein
aggregates) and changes in extracellular signals (e.g., reduced IGF1 sig-
naling and proinflammatory cytokines) (Ho et al., 2016).
7 | ASTROCYTE AGING
A major component of the evolving “glial doctrine” is that astrocytes,
the most abundant type of glial cell, trigger key molecular processes
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that lead to brain aging. Surprisingly, aging is characterized by a high
percentage of astrocytes with a reactive phenotype, even when no
sign of disease is apparent. Since mice lacking the microglial proin-
flammatory cytokines (IL‐1α, TNF and C1q) are protected against
aging‐associated reactive astrogliosis, this suggests that microglia are
at least in part responsible for inducing this normal brain “inflammag-
ing” phenomenon (Clarke et al., 2018). The total astrocyte number
within the CNS increases by 20% in the aged brain, whereas the
number of oligodendrocytes and microglia remain constant (Pilegaard
& Ladefoged, 1996). Aged astrocytes express higher levels of gap
junctions and elevated levels of the cytoplasmic proteins, glial fibril-
lary acidic protein (GFAP), S100β (involved in calcium binding), and
tau (although not neurofibrillary tangles) (Cotrina & Nedergaard,
2002).
Gene expression profiling from aging brains in mice has revealed
that aging is associated with an inflammatory response and oxidative
stress, with resemblance to human neurodegeneration (Lee, Wein-
druch, & Prolla, 2000). The GFAP gene undergoes a twofold increase
TABLE 2 Comparison of in vitro paradigms to model human neurodegeneration
Aging Hallmark induced pluripotent stem cells (iPSC)‐derived neurons Aged iPSC‐derived neurons
Perturbed cellular
architecture and
functional maturity
Intact (fetal‐equivalent) cellular architecture which do not fully
capture age‐related cellular phenotypes.
Dendrite length and number are not significantly affected.
Cells are less prone to activating cell death program.
Electrophysiological immaturity with resting membrane potential
relatively depolarized, input resistance raised, with slower kinetics
and smaller amplitude.
Aged cells have enhanced nuclear folding and
blebbing. The nuclei are disorganized and appear
misshapen.
Reduced number and shorter dendrites.
Cells exhibit increased susceptibility to apoptosis
and cellular stressors.
Electrophysiological maturity with respect to resting
membrane potential, capacitance, action potential
threshold, and amplitude.
Impaired nuclear‐
cytoplasmic
compartmentalization
iPSC exhibit tightly regulated compartmentalization of nuclear and
cytoplasmic proteins as well as the nuclear pore complexes.
Age‐dependent loss of nucleocytoplasmic
compartmentalization. Cells display age‐associated
decreases in nuclear transport with loss of nuclear
cytoplasmic receptors for example, RanBP17.
Higher levels of soluble detergent‐resistant TDP‐
43.
Gene expression
signature and splicing
The transcriptome exhibits no molecular features of aging Display an age‐specific transcriptional profile.
Return of differentially expressed gene transcripts
found in aged neurons involved with aging,
synaptic transmission, neuron generation and
differentiation, stress response, inflammation,
calcium homeostasis, nuclear pore, and splicing.
Epigenetic Methylation signatures resemble embryonic stem cells (ESCs).
However, after reprogramming iPSCs harbor residual DNA
methylation signatures from their donor cells (epigenetic memory)
with preference for differentiation into their original cell lineage
Epigenome modifications and histone methylation
patterns are similar to aged neurons with net loss
of heterochromatin, although there are
reproducible increases in DNA methylation at
some CpG sites and decreases at others. These
alterations are detectable prior to aberrations in
cellular architecture.
Telomeres Telomere length resembles ESCs; however, heterogeneity in
telomere length has been found.
Length of telomeres is abrogated, and extended
culture leads to progressive telomere shortening
and loss of self‐renewal.
DNA damage DNA repair mechanisms function efficiently. There is accumulation of DNA damage (gamma
H2AX) and reduced capacity of the DNA repair
mechanisms leading to senescence reflecting
cellular aging.
Mitochondrial
dysfunction
Glycolysis > mitochondrial oxidative metabolism, resembling ESCs. Aged neurons display decreased oxidative
phosphorylation‐related gene expression, impaired
axonal mitochondrial morphologies, lower
mitochondrial membrane potentials, reduced
energy production, and increased mitochondrial
radical oxygen species which leads to increased
oxidized proteins.
References Cooper et al. (2012), de Boni et al. (2018), Israel et al. (2012), Lister
et al. (2011), Mertens et al. (2015), Miller et al. (2013), Nguyen
et al. (2011), Ohi et al. (2011), Seibler et al. (2011), Simara et al.
(2017), Wang et al. (2012), Xu et al. (2013)
Batista et al. (2011), Gunhanlar et al. (2018), Ho
et al. (2011), Kim et al. (2018), Liu et al. (2011),
Mertens et al. (2015), Miller et al. (2013), Nguyen
et al. (2011), Simara et al. (2017), Vera et al.
(2016), Zhang et al. (2011)
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in gene expression, which maybe in response to these injurious stim-
uli. Indeed, inflammation and oxidative stress have been shown to
induce alterations in astrocyte calcium signaling, thereby impacting
on astrocytic modulation of neuronal function (Squier & Bigelow,
2000). Using RNA sequencing of astrocytes from different brain
regions across the lifespan of the mouse, Clarke and coworkers were
able to demonstrate that aged astrocytes significantly upregulate
several potentially detrimental astrocyte reactive genes. Distinguish-
ing astrocyte changes between normal brain aging and early patho-
logical neurodegeneration will be a crucial challenge in order to
identify specific therapeutic targets.
8 | SUMMARY
Over the past decade, the iPSC field has made significant advances
permitting generation of unlimited numbers of any differentiated cell
type with the genetics of diseased patients. Producing these models
has provided a platform to investigate cellular mechanisms of the
disease, thus releasing the brake on the understanding of human
neurological diseases, which have been notoriously challenging to
study due to difficulties accessing patient tissue. Although differenti-
ation protocols provide a novel perspective that cannot be achieved
from animal models, differentiating rejuvenated cells from patients
with ALS has thus far not fully integrated cellular aging into disease
modeling paradigms. Across the iPSC spectrum, differentiated cells
repeatedly retain embryonic characteristics and lack the crucial aging
component that precedes the disease.
The issue facing the field now is whether we can complement
the iPSC platform with an induced aging paradigm that incorporates
aging‐associated molecular pathology. To overcome this hurdle,
numerous strategies have been employed to experimentally manipu-
late aging in vitro; nonetheless, the field still requires a systematic
and comprehensive multi‐pronged approach that addresses the dif-
ferent cellular and molecular hallmarks of aging in a standardized
and reproducible manner. Recent work replicating complex in vivo
conditions has improved disease models but whether this helps to
recapture aging per se remains to be determined. Although these
approaches hasten the development of disease‐related phenotypes,
given their artificial nature, it must be questioned whether they
authentically recapitulate the aging process. The capacity to repro-
gram and differentiate cells that are fully functional and appropri-
ately aged bestows a vital milestone on the path to generating
optimal iPSC models of ALS.
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